JAAD Pilot Pits Mometasone Against Crisaborole and Tofacitinib

The Journal of the American Academy of Dermatology has published a randomized, assessor-blinded, triple-arm pilot study comparing three topical treatments head-to-head in mild to moderate atopic dermatitis: mometasone furoate 0.1% ointment, crisaborole 2% ointment, and tofacitinib 2% ointment, all applied twice daily. The paper appears in Volume 95, Issue 5, dated November 2026, and carries authors Shreya K. Gowda and Neetu Bhari.

The design matters for anyone reading the results. Three arms, randomization, and blinded assessors put the study a step above open-label comparisons, even at pilot scale. Twice-daily dosing was held constant across all three ointments, so the comparison isolates the active rather than the regimen.

Why compare these three actives?

Mometasone furoate 0.1% is a mid-potency corticosteroid and a long-standing workhorse for atopic dermatitis flares. Crisaborole 2%, a non-steroidal PDE4 inhibitor, holds FDA approval for mild to moderate disease in patients as young as 3 months. Tofacitinib 2% ointment, a topical JAK inhibitor, is not approved for atopic dermatitis in every market, which makes comparative data against approved agents clinically interesting.

A head-to-head format against a steroid benchmark lets clinicians weigh steroid-sparing alternatives on efficacy rather than on package inserts alone.

What does the study cover?

The trial enrolled patients with mild to moderate atopic dermatitis and randomized them to one of the three twice-daily ointments. Assessors blinded to treatment assignment scored outcomes, a safeguard against the rating bias that plagues topical-steroid comparisons in particular.

The November 2026 publication date means the full efficacy endpoints, safety signals, and statistical caveats are now available in JAAD Volume 95, Issue 5. Derm Field has not independently verified the outcome data beyond the journal's listing, and readers should consult the full text for the primary endpoint results.

Why head-to-head pilot data matter

Most topical atopic dermatitis comparisons rest on indirect evidence: each agent's pivotal trials against vehicle or against different comparators, stitched together in network meta-analyses. Direct triple-arm comparisons are rarer, and pilot studies like this one set the hypotheses that larger trials then test.

For practice, the stakes are concrete. Clinicians balancing steroid phobia, crisaborole's approved pediatric niche, and the regulatory patchwork around topical JAK inhibitors need comparative numbers to sequence therapy in mild to moderate disease.

Whether the pilot's findings hold at scale will depend on confirmatory trials, but the design gives the field a template worth watching.